
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell RNA sequencing dataset of breast cancer tissue, I will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **FASN (Fatty Acid Synthase):** Involved in lipogenesis, often upregulated in cancer cells for membrane synthesis.<br>- **SLC7A2 (Solute Carrier Family 7 Member 2):** Amino acid transporter, important for cellular metabolism.<br>- **CA12 (Carbonic Anhydrase 12):** Involved in pH regulation, often expressed in cancer cells.<br>- **MAPT (Microtubule Associated Protein Tau):** Stabilizes microtubules, associated with cell structure.<br>- **SREBF1 (Sterol Regulatory Element Binding Transcription Factor 1):** Regulates lipid homeostasis.<br>- **IL6ST (Interleukin 6 Signal Transducer):** Part of the IL-6 receptor complex, involved in immune signaling.<br><br>### Step 2: List the Key Cell Type Markers<br>- **MUC1 (Mucin 1):** A glycoprotein expressed on the apical surface of epithelial cells, often overexpressed in breast cancer.<br>- **PGR (Progesterone Receptor):** A nuclear receptor, indicative of hormone-responsive breast cancer cells.<br>- **KRT19 (Keratin 19):** An epithelial marker, often used to identify epithelial cells in breast tissue.<br>- **KRT7 (Keratin 7):** Another epithelial marker, common in glandular and transitional epithelium.<br>- **PRLR (Prolactin Receptor):** Involved in mammary gland development, often expressed in breast tissue.<br>- **ANKRD30A (Ankyrin Repeat Domain 30A):** Known to be expressed in breast tissue, particularly in luminal cells.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and literature on breast cancer, the markers MUC1, PGR, KRT19, KRT7, and PRLR are strongly associated with epithelial cells, particularly luminal epithelial cells in the breast. These markers are often used to identify luminal subtypes of breast cancer.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of epithelial markers (MUC1, KRT19, KRT7) and hormone receptors (PGR, PRLR), the most probable general cell type is **epithelial cells**. Given the context of breast cancer tissue, these are likely to be **luminal epithelial cells**.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Luminal A Breast Cancer Cells:** Characterized by the expression of hormone receptors (PGR, PRLR) and low proliferation markers.<br>2. **Luminal B Breast Cancer Cells:** Similar to Luminal A but with higher proliferation and possibly higher expression of genes like FASN and SREBF1.<br>3. **Normal Luminal Epithelial Cells:** Express markers like KRT19 and KRT7 but may have lower expression of cancer-associated markers like MUC1.<br><br>The most likely subtype, given the presence of PGR, PRLR, and epithelial markers, is **Luminal A Breast Cancer Cells**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of luminal epithelial cells. The expression of hormone receptors and epithelial markers strongly indicates a luminal subtype of breast cancer, with Luminal A being the most probable due to the presence of PGR and PRLR. This subtype is characterized by hormone receptor positivity and lower proliferation compared to Luminal B.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency:**<br>   - The key functional markers (FASN, SLC7A2, CA12, MAPT, SREBF1, IL6ST) and key cell type markers (MUC1, PGR, KRT19, KRT7, PRLR, ANKRD30A) are all present in the provided marker list.<br>   - The markers used to identify the cell type as luminal epithelial cells, particularly Luminal A Breast Cancer Cells, are consistent with known literature and databases for breast cancer tissue.<br><br>2. **Mixed Cell Type Consideration:**<br>   - The analysis does not strongly suggest the presence of multiple distinct cell types within the cluster. The markers predominantly support the identification of luminal epithelial cells, specifically Luminal A Breast Cancer Cells.<br>   - There is no indication of a mixed cell population that would require further investigation.<br><br>The annotation is well-supported by the marker list and aligns with the known characteristics of luminal epithelial cells in breast cancer tissue.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">epithelial cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Luminal A Breast Cancer Cells</li><li>Luminal B Breast Cancer Cells</li><li>Normal Luminal Epithelial Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">85</div>
                        <div class="scoring-content">
                            The annotation results provided for the single-cell RNA sequencing dataset of breast cancer tissue are generally well-executed, with a few areas that could be improved. <br><br>1. **Correctness of Annotations**: The annotations correctly identify the main cell type as epithelial cells, specifically luminal epithelial cells, which is consistent with the marker list and the context of breast cancer. The identification of Luminal A Breast Cancer Cells as the most probable subtype is well-supported by the presence of hormone receptors (PGR, PRLR) and epithelial markers (MUC1, KRT19, KRT7).<br><br>2. **Balanced Consideration of Markers**: The analysis effectively balances the use of functional markers (e.g., FASN, SLC7A2, CA12) and cell type markers (e.g., MUC1, PGR, KRT19). However, there is a slight overemphasis on hormone receptor markers, which may overshadow other important markers that could suggest additional subtypes or mixed cell populations. The analysis could benefit from a more detailed exploration of markers like SREBF1 and IL6ST, which might indicate metabolic or immune-related characteristics.<br><br>3. **General Picture of Cell Populations**: The annotation provides a comprehensive view of the cell types present, focusing on luminal epithelial cells. However, the analysis does not fully explore the possibility of mixed cell populations or other subtypes that might be present, given the diverse marker list. For instance, markers like COL1A1, COL3A1, and SPARC could suggest the presence of stromal or mesenchymal cells, which are not discussed.<br><br>4. **Consideration of Marker Rank**: The analysis does not explicitly consider the rank of the markers, which could provide additional insights into the relative importance of each marker in defining the cell type. For example, markers appearing earlier in the list might have a higher expression or significance in the dataset.<br><br>Overall, the annotation is scientifically accurate and provides a solid foundation for understanding the cell populations in the dataset. However, it could be improved by considering the rank of markers and exploring the potential for mixed cell populations or additional subtypes.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    